Expression profiling on subclasses of primary parotid gland carcinomas.
cancer
gene expression
nanostring
pancancer pathway
salivary gland
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
10 Nov 2020
10 Nov 2020
Historique:
received:
11
05
2020
accepted:
17
10
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
epublish
Résumé
The underlying molecular mechanisms of parotid gland carcinomas (PGC) are still unknown. Knowledge about the tumor-driving signaling pathways is necessary either for diagnostics or developing new therapeutic options in this heterogeneous and rare entity. 94 matching RNA formalin-fixed and paraffin-embedded tissue samples from PGC and the corresponding non-tumor area, RNA quality and quantity were sufficient for gene expression profiling of 770 genes using the NanoString's nCounter technology. Oncogenic and tumor suppressor genes were examined in the three common PGC tumor entities: adenoid cystic carcinoma (ACC), adenocarcinoma NOS (AC-NOS), and mucoepidermoid carcinoma (MEC). Expression profiling and subsequent hierarchical cluster analysis clearly differentiated between non-tumor gland tissue samples and PGC. In addition expression pattern of all three entities differed. The extensive pathway analysis proved a prominent dysregulation of the Wnt signaling pathway in the three PGC entities. Moreover, transcript upstream analysis demonstrated a pronounced activation of the PI3K pathway in ACC and MEC. Our findings revealed divergent molecular expression profiles in MEC, ACC and AC-NOS that are presently studied for their potential application in PGC diagnostics. Importantly, identification of Wnt and PI3K signaling in PGC revealed novel options of PGC therapy.
Identifiants
pubmed: 33227073
doi: 10.18632/oncotarget.27797
pii: 27797
pmc: PMC7665229
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4123-4137Informations de copyright
Copyright: © 2020 Meinrath et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Biomed Mater Eng. 2015;26 Suppl 1:S2145-53
pubmed: 26405993
Oral Oncol. 2011 Jul;47(7):677-82
pubmed: 21612974
Clin Cancer Res. 2011 Sep 1;17(17):5530-7
pubmed: 21775534
J Clin Oncol. 2006 Jun 10;24(17):2673-8
pubmed: 16763282
Oncogene. 1998 Mar;16(11):1409-16
pubmed: 9525740
Mol Cancer Ther. 2011 Mar;10(3):558-65
pubmed: 21216929
Oral Oncol. 2012 Feb;48(2):179-85
pubmed: 21968090
Annu Rev Med. 2016;67:11-28
pubmed: 26473415
Clin Cancer Res. 2020 Jun 15;26(12):2859-2870
pubmed: 32060100
Oral Oncol. 2013 Sep;49(9):903-910
pubmed: 23850296
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
J Oral Maxillofac Surg. 2005 Jul;63(7):917-28
pubmed: 16003616
Oncotarget. 2015 Jul 20;6(20):18224-37
pubmed: 26053092
Eur J Cancer. 2011 Sep;47(14):2150-7
pubmed: 21802280
Eur J Surg Oncol. 2008 Aug;34(8):932-7
pubmed: 18358679
Oral Oncol. 2014 Aug;50(8):683-90
pubmed: 24856188
Target Oncol. 2017 Oct;12(5):623-641
pubmed: 28653295
Head Neck. 2010 Oct;32(10):1402-11
pubmed: 20029981
Oncogene. 2016 Oct 27;35(43):5585-5596
pubmed: 27065333
Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):79-85
pubmed: 9054880
BMC Cancer. 2015 Dec 26;15:1015
pubmed: 26706028
Int J Cancer. 2008 Oct 1;123(7):1593-600
pubmed: 18649356
Nat Genet. 1997 Feb;15(2):170-4
pubmed: 9020842
Oncotarget. 2017 Sep 21;8(58):98298-98311
pubmed: 29228690
Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):94-101
pubmed: 18209144
Clin Colorectal Cancer. 2011 Mar 1;10(1):63-9
pubmed: 21609938
Eur Arch Otorhinolaryngol. 2014 Apr;271(4):647-63
pubmed: 23649507
Int J Oncol. 2008 May;32(5):1041-7
pubmed: 18425330
Cell. 1988 Nov 18;55(4):619-25
pubmed: 3180222
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Sci Rep. 2017 Sep 11;7(1):11069
pubmed: 28894165